Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review
Article Sidebar
Submitted
21 August 2024
21 August 2024
Published
28 February 2025
28 February 2025
Abstract
Triple-negative breast cancer is an aggressive and poor prognosis subtype of breast cancer. Eribulin has shown promise in the treatment of metastatic triple-negative breast cancer (mTNBC). This review aimed to provide a specific description, evidence, and discussion of the efficacy and safety of eribulin both as monotherapy and in combination with another agent in patients with mTNBC. The search was conducted in five databases (PubMed, ScienceDirect, PLoS One, Wiley Online Library, and Cochrane Library) towards published articles during the 2013-2023 period. A total of 237 articles were identified. After removing 69 duplicates, 168 articles underwent the screening process and 10 articles met the research criteria. Eribulin monotherapy effectiveness profile includes: overall survival (10.8-17.6 months), progression-free survival (2.8-3.2 months), partial response (21.0%-58.7%), progressive disease (15.5% -47.0%), and stable disease (28.8%-32%). However, there were no cases of complete response. Combination of eribulin with other agents' effectiveness profiles includes: overall survival (8.3-14.5 months), PFS (2.6-8.1 months), partial response (31.8-76.0%), complete response (2.4-8%), progressive disease (8.0-28%), and stable disease (8.0-52.3%). Eribulin monotherapy's safety profile is similar to that of combination therapy. No grade 5 adverse event was reported during monotherapy or in combination with other agents. The grade 4 adverse events reported are neutropenia, leukopenia, thrombocytopenia, anemia, peripheral neuropathy, fatigue, diarrhea, vomiting, dyspnea, back pain, arthralgia, febrile neutropenia, dyspnea, constipation, general physical health deterioration, alopecia. The all-grade adverse events with a percentage above 50% are neutropenia, leukopenia, thrombocytopenia, asthenia, alopecia, elevated AST, elevated ALT, hand-foot syndrome, fatigue, anemia, peripheral neuropathy, oral mucositis, and nausea.
Full text article
Generated from XML file
References
1. Nwagu GC, Bhattarai S, Swahn M, Ahmed S, Aneja R. Prevalence and Mortality of Triple-Negative Breast Cancer in West Africa: Biologic and Sociocultural Factors. JCO Glob Oncol. 2021; 7:1129–40. DOI: 10.1200/go.21.00082; PMCID: PMC8457872; PMID: 34264759
2. Almansour NM. Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Front Mol Biosci. 2022;9:836417. DOI: 10.3389/fmolb.2022.836417; PMCID: PMC8824427; PMID: 35145999
3. Gaol DLHL, Rizki KA, Soemitro MP. Incidence Rate and Clinical Characteristics of Triple Negative Breast Cancer Patients in Hasan Sadikin Hospital, for the Last Five Years. J Soc Res. 2023; 2(5):1558-62. DOI: 10.55324/josr.v2i5.845
4. Li S, Bao C, Huang L, Wei JF. Current therapeutic strategies for metastatic triple-negative breast cancer: From pharmacists’ perspective. J Clin Med. 2022;11(20):6021. DOI: 10.3390/jcm11206021; PMCID: PMC9604829; PMID: 36294342
5. Kazmi S, Chatterjee D, Raju D, Hauser R, Kaufman PA. Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine. Breast Cancer Res Treat. 2020;184(2):559-65. DOI: 10.1007/s10549-020-05867-0; PMCID: PMC7599186; PMID: 32808239
6. Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res. 2018;8(5):1483-507. DOI: 10.1007/s13346-018-0551-3; PMCID: PMC6133085; PMID: 29978332
7. Zhang X, Yeung KT. Metastatic Triple-Negative Breast Cancer. Curr Breast Cancer Rep. 2023;15:288-97. DOI: 10.1007/s12609-023-00493-3
8. Krasniqi E, Pizzuti L, Valerio MR, Capomolla E, Botti C, Sanguineti G, et al. Second-line eribulin in triple negative metastatic breast cancer patients. Multicentre retrospective study: the TETRIS trial. Int J Med Sci. 2021;18(10):2245-50. DOI: 10.7150/ijms.54996; PMCID: PMC8040412; PMID: 33859534
9. Asano M, Matsui J, Towle MJ, Wu J, McGonigle S, Boisferon MHDE, et al. Broad-spectrum preclinical antitumor activity of eribulin (Halaven®): combination with anticancer agents of differing mechanisms. Anticancer Res. 2018;38(6):3375-85. DOI: 10.21873/anticanres.12604; PMID: 29848686
10. Kenny L, Beresford M, Brown I, Misra V, Kristeleit H. Eribulin for the treatment of advanced breast cancer: A prospective observational registry study. Eur J Cancer Care. 2022;31(6):e13747. DOI: 10.1111/ecc.13747; PMCID: PMC9787722; PMID: 36336468
11. Zhou Y, Yang J. Narrative review of current status and recommendations in treatment for advanced triple-negative breast cancer. Transl Breast Cancer Res. 2022;3:17. DOI: 10.21037/tbcr-22-12; PMCID: PMC11093051; PMID: 38751541
12. Gui X, Liang X, Li H. Effectiveness, safety, and impact on quality of life of eribulin‐based therapy in heavily pretreated patients with metastatic breast cancer: A real‐world analysis. Cancer Med. 2023;12(6):16793-804. DOI: 10.1002/cam4.6301; PMCID: PMC10501238; PMID: 37403746
13. Garrone O, Miraglio E, Vandone AM, Vanella P, Lingua D, Merlanno MC. Eribulin in advanced breast cancer: safety, efficacy and new perspectives. Futur Oncol. 2017;13(30):2759-69. DOI: 10.2217/fon-2017-0283; PMID: 29219017
14. Tanni KA, Truong CB, Johnson BS, Qian J. Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;163:103375. DOI: 10.1016/j.critrevonc.2021.103375; PMID: 34087344
15. Greenhalgh T, Thorne S, Malterud K. Time to challenge the spurious hierarchy of systematic over narrative reviews? Eur J Clin Invest. 2018;48(6):e12931. DOI: 10.1111/eci.12931; PMCID: PMC6001568; PMID: 29578574
16. Mertz S, Benjamin C, Girvalaki C, Cardone A, Gono P, May SG, et al. Progression-free survival and quality of life in metastatic breast cancer: The patient perspective. Breast. 2022;65:84-90. DOI: 10.1016/j.breast.2022.07.006; PMCID: PMC9307669; PMID: 35870420
17. Ruchalski K, Dewan R, Sai V, McIntosh LJ, Braschi-Amirfarzan M. Imaging response assessment for oncology: An algorithmic approach. Eur J Radiol Open. 2022;9:100426. DOI: 10.1016/j.ejro.2022.100426; PMCID: PMC9184854; PMID: 35693043
18. Subbiah V, Chuang HH, Gambhire D, Kairemo K. Defining clinical response criteria and early response criteria for precision oncology: current state-of-the-art and future perspectives. Diagnostics. 2017;7(1):10. DOI: 10.3390/diagnostics7010010; PMCID: PMC5373019; PMID: 28212290
19. U.S. Department of Health and Human Services. Common terminology criteria for adverse events v5.0. Washington DC: U.S. Department of Health and Human Services; 2017.
20. Le-Rademacher JG, Hillman S, Storrick E, Mahoney MR, Thall PF, Jatoi A, et al. Adverse event burden score a versatile summary measure for cancer clinical trials. Cancers. 2020;12(11):3251. DOI: 10.3390/cancers12113251; PMCID: PMC7694214; PMID: 33158080
21. Masuda N, Ono M, Mukohara T, Yasojima H, Shimoi T, Kobayashi K, et al. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort. Eur J Cancer. 2022;168:108-18. DOI: 10.1016/j.ejca.2022.03.004; PMID: 35500404
22. Pivot X, Marmé F, Koenigsberg R, Guo M, Berrak E, Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol. 2016;27(8):1525-31. DOI: 10.1093/annonc/mdw203; PMCID: PMC4959925; PMID: 27177860
23. Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, et al. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial. Eur J Cancer. 2016;60:117-24. DOI: 10.1016/j.ejca.2016.03.010; PMID: 27107326
24. Mougalian SS, Copher R, Kish JK, McAllister L, Wang Z, Broscious M, et al. Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting. Cancer Med. 2018;7(9):4371-8. DOI: 10.1002/CAM4.1705; PMCID: PMC6144147; PMID: 30066497
25. Dranitsaris G, Gluck S, Faria C, Cox D, Rugo H. Comparative Effectiveness Analysis of Monotherapy with Cytotoxic Agents in Triple-negative Metastatic Breast Cancer in a Community Setting. Clin Ther. 2015;37(1):134-44. 2015. DOI: 10.1016/j.clinthera.2014.10.023; PMID: 25433768
26. Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H, et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10(3):e004291. DOI: 10.1136/jitc-2021-004291; PMCID: PMC8961177; PMID: 35338088
27. Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, et al. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di R. ESMO Open. 2021;6(1):100019. DOI: 10.1016/j.esmoop.2020.100019; PMCID: PMC7808100; PMID: 33399082
28. Lee JS, Yost SE, Blanchard S, Schmolze D, Yin HH, Pillai R, et al. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2019;21(1):119. DOI: 10.1186/s13058-019-1202-4; PMCID: PMC6839083; PMID: 31703728
29. Di Cosimo S, La Verde N, Moretti A, Cazzaniga ME, Generali D, Bianchi GV, et al. Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. PLoS One. 2019;14(8):e0220644. DOI: 10.1371/journal.pone.0220644; PMCID: PMC6685628; PMID: 31390375
30. Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, et al. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. Eur J Cancer. 2019;109:84-91. DOI: 10.1016/j.ejca.2018.11.014; PMID: 30703739
31. Zhou HL, Chen DD. Prognosis of patients with triple-negative breast cancer: a population-based study from SEER database. Clin Breast Cancer. 2023;23(3):e85-94. DOI: 10.1016/j.clbc.2023.01.002; PMID: 36669957
32. Celik A, Berg T, Jensen MB, Nielsen HM, Kümler I, Glavicic V, et al. Real-World Survival and Treatment Regimens Across First-to Third-Line Treatment for Advanced Triple-Negative Breast Cancer. Breast Cancer Basic Clin Res. 2023;17:11782234231203292. DOI: 10.1177/11782234231203292; PMCID: PMC10552450; PMID: 37810797
33. Skinner KE, Haiderali A, Huang M, Schwartzberg LS. Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer. Futur Oncol. 2021;17(8):931-41. DOI: 10.2217/fon-2020-1021; PMID: 33207944
34. Kesireddy M, Elsayed L, Shostrom VK, Agarwal P, Asif S, Yellala A, et al. Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis. Cancers, 2024;16(10):1791. DOI: 10.3390/cancers16101791; PMCID: PMC11120599; PMID: 38791870
35. O’Shaughnessy J, Cortes J, Twelves C, Goldstein LJ, Alexis K, Xie R, et al. Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. Sci Rep. 2020;10(1):11203. DOI: 10.1038/s41598-020-66980-0; PMCID: PMC7343788; PMID: 32641747
36. Oey O, Wijaya W, Redfern A. Eribulin in breast cancer: Current insights and therapeutic perspectives. World J Exp Med. 2024;14(2):92558. DOI: 10.5493/wjem.v14.i2.92558; PMCID: PMC11212747; PMID: 38948420
37. Giulietti M, Piva F, Cecati M, Maggio S, Guescini M, Saladino T, et al. Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells. Cells. 2024;13(6):479. DOI: 10.3390/cells13060479; PMCID: PMC10969587; PMID: 38534323
38. O’Shaughnessy J, Kaklamani V, Kalinsky K. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. Futur Oncol. 2019;15(14):1641-53. DOI: 10.2217/fon-2018-0936; PMID: 30892083
39. Takahashi-Ruiz L, Fermaintt CS, Wilkinson NJ, Chen PYW, Mooberry SL, Risinger AL. The microtubule destabilizer eribulin synergizes with STING agonists to promote antitumor efficacy in triple-negative breast cancer models. Cancers. 2022;14(23):5962. DOI: 10.3390/cancers14235962; PMCID: PMC9740651; PMID: 36497445
40. Yuan P, Xu B. Clinical utility of eribulin mesylate in the treatment of breast cancer: A Chinese perspective. Breast Cancer Targets Ther. 2021;13:135-50. DOI: 10.2147/BCTT.S231298; PMCID: PMC7917473; PMID: 33658845
41. Zhang R, Chen Y, Liu X, Gui X, Zhu A, Jiang H, et al. Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting. Front Oncol. 2023;13:1076469. DOI: 10.3389/fonc.2023.1076469; PMCID: PMC10314217; PMID: 37397355
42. Jiang M, Shao B, Wan D, Liu J, He M, Chai Y, et al. Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study. Ther Adv Med Oncol. 2023;15:17588359231204856. DOI: 10.1177/17588359231204856; PMCID: PMC10571693; PMID: 37841751
43. Huang W, Wang C, Shen Y, Chen Q, Huang Z, Liu J, et al. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer. BMC Cancer. 2024;24(1):39. DOI: 10.1186/s12885-023-11790-6; PMCID: PMC10768098; PMID: 38182995
44. Wang K, Yang J, Wang B, Liu Q, Wang X, Yin Y, et al. Expert consensus on the clinical application of immunotherapy in breast cancer: 2024. Transl Breast Cancer Res. 2024;5:9. DOI: 10.21037/tbcr-24-15; PMCID: PMC11094404; PMID: 38751677
45. Ou Y, Wang M, Xu Q, Sun B, Jia Y. Small molecule agents for triple negative breast cancer: Current status and future prospects. Transl Oncol. 2024;41:101893. DOI: 10.1016/j.tranon.2024.101893; PMCID: PMC10840364; PMID: 38290250
46. DiPiro JT, Yee GC, Haines ST, Niolin TD, Ellingrod VL, Posey M. DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, 12th Edition. New York: McGraw Hill; 2023.
47. Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121. DOI: 10.1186/s13045-022-01341-0; PMCID: PMC9422136; PMID: 36038913
48. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727-42. PMCID: PMC7136921; PMID: 32266087
49. Marra A, Trapani D, Viale G, Cristiciello C, Curigliano G. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer. 2020;6:54. DOI: 10.1038/s41523-020-00197-2; PMCID: PMC7568552; PMID: 33088912
50. Chen Z, Lu X, Koral K. The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2020;14(11):1017-24. DOI: 10.1080/17474124.2020.1807939; PMID: 32762583
51. Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475-95. DOI: 10.1016/j.annonc.2021.09.019; PMID: 34678411
52. Telli ML, Gradishar WJ, Ward JH. NCCN Guidelines Updates: Breast Cancer. J Natl Compr Canc Netw. 2019;17(5.5):552-5. DOI: 10.6004/jnccn.2019.5006; PMID: 31117035
53. Gradishar W, Salerno KE. NCCN Guidelines Update: Breast Cancer. J Natl Compr Canc Netw. 2016;14(5 Suppl):641-4. DOI: 10.6004/jnccn.2016.0181; PMID: 27226503
54. Heeke AL, Tan AR. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. Cancer Metastasis Rev. 2021;40(2):537-47. DOI: 10.1007/s10555-021-09972-4; PMCID: PMC8184866; PMID: 34101053
55. López-Álvarez M, González-Aguilera C, Moura DS, Sánchez-Bustos P, Mondaza-Hernández JL, Martín-Ruiz M, et al. Efficacy of eribulin plus gemcitabine combination in L-sarcomas. Int J Mol Sci. 2022;24(1):680. DOI: 10.3390/ijms24010680; PMCID: PMC9820645; PMID: 36614121
56. Lheureux S, Oza AM, Laurie SA, Halford R, Jonker D, Chen E, et al. A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium. Br J Cancer. 2015;113(11):1534-40. DOI: 10.1038/bjc.2015.343; PMCID: PMC4705880; PMID: 26554651
57. Manousakis E, Miralles CM, Esquerda MG, Wright RGH. CDKN1A/p21 in Breast Cancer: Part of the Problem, or Part of the Solution? Int J Mol Sci. 2023;24(24):17488. DOI: 10.3390/ijms242417488; PMCID: PMC10743848; PMID: 38139316
58. El Guerrab A, Bamdad M, Bignon YJ, Penault-Llorca F, Aubel C. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells. Sci Rep. 2020;10:6367. DOI: 10.1038/s41598-020-63310-2; PMCID: PMC7156377; PMID: 32286420
59. Zhang H, Jiang R, Zhu J, Sun KN, Huang Y, Zhou HH, et al. PI3K/AKT/mTOR signaling pathway: An important driver and therapeutic target in triple-negative breast cancer. Breast Cancer. 2024;31(4):539-51. DOI: 10.1007/s12282-024-01567-5; PMCID: PMC11194209; PMID: 38630392
60. Roviello G, Milani M, Gobbi A, Cappelletti MR, Zanotti L, Senti C, et al. A phase Ib open-label study to assess the safety and tolerability of everolimus in combination with eribulin in triple-negative breast cancers. Clin Breast Cancer. 2016;16(3):e57-9. DOI: 10.1016/j.clbc.2016.02.012; PMID: 26943987
61. Mazumdar A, Tahaney WM, Hill JL, Zhang Y, Ramachandran S, Kawedia J, et al. Targeting the mTOR pathway for the prevention of ER-negative breast cancer. Cancer Prev Res. 2022;15(12):791-802. DOI: 10.1158/1940-6207.CAPR-22-0106; PMCID: PMC9762336; PMID: 35981902
62. He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):425. DOI: 10.1038/s41392-021-00828-5; PMCID: PMC8677728; PMID: 34916492
63. Yang R, Li Y, Wang H, Qin T, Yin X, Ma X. Therapeutic progress and challenges for triple negative breast cancer: Targeted therapy and immunotherapy. Mol Biomed. 2022;3(1):8. DOI: 10.1186/s43556-022-00071-6; PMCID: PMC8894518; PMID: 35243562
64. Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol. 2019;30(7):1051-60. DOI: 10.1093/annonc/mdz133; PMID: 31050709
65. Wen W, Marcinkowski E, Luyimbazi D, Luu T, Xing Q, Yan J, et al. Eribulin synergistically increases anti-tumor activity of an mTOR inhibitor by inhibiting pAKT/pS6K/pS6 in triple negative breast cancer. Cells. 2019;8(9):1010. DOI: 10.3390/cells8091010; PMCID: PMC6770784; PMID: 31480338
66. Seshadri P, Deb B, Kumar P. Multifarious targets beyond microtubules—role of eribulin in cancer therapy. Front Biosci. 2021;13(2):157-72. DOI: 10.52586/S559; PMID: 34879468
67. Lin YY, Gao HF, Yang X, Zhu T, Zheng XX, Ji F, et al. Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis. Breast. 2022;66. DOI: 10.1016/j.breast.2022.08.006; PMCID: PMC9587342; PMID: 36265208
68. Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer. 2016;10:25-36. DOI: 10.4137/BCBCR.S32783; PMCID: PMC4807882; PMID: 27042088
69. Sharif-Askari B, Panasci L, Aloyz R. PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin. Front Biosci. 2023;28(3):52. DOI: 10.31083/j.fbl2803052; PMID: 37005765
70. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017; 377(6):523-33. DOI: 10.1056/NEJMoa1706450; PMID: 28578601
71. Zerdan MB, Ghorayeb T, Saliba F, Allam S, Zerdan MB, Yaghi M, et al. Triple negative breast cancer: updates on classification and treatment in 2021. Cancers. 2022;14(5):1253. DOI: 10.3390/cancers14051253; PMCID: PMC8909187; PMID: 35267561
72. Swami U, Shah U, Goel S. Eribulin in cancer treatment. Mar Drugs. 2015;13(8):5016-58. DOI: 10.3390/md13085016; PMCID: PMC4557013; PMID: 26262627
73. Ro J, Cheng FTF, Sriuranpong V, Villalon A, Smruti BK, Tsang J, et al. Patient management with eribulin in metastatic breast cancer: a clinical practice guide. J Breast Cancer. 2016;19(1):8-17. DOI: 10.4048/jbc.2016.19.1.8; PMCID: PMC4822111; PMID: 27066091
74. Chen C, Wang J, Zhao Q. Hematologic adverse events (HAEs) of Eribulin used in treating metastatic breast cancer (MBC): a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2018;11(6):5409-17.
75. Aytan J, Bukhari MAS. Review Use of biologics in SLE: a review of the evidence from a clinical perspective. Rheumatology. 2016;55(5):775-9. DOI: 10.1093/rheumatology/kev346; PMID: 26424838
76. Perez-Garcia JM, Cortes J. The safety of eribulin for the treatment of metastatic breast cancer. Expert Opin Drug Saf. 2019;18(5):347-55. DOI: 10.1080/14740338.2019.1608946; PMID: 31107111
77. Strom BL, Kimmel SE, Hennessy S. Textbook of Pharmacoepidemiology. 3rd Edition. Chichester: John Wiley & Sons; 2022.
Read More
2. Almansour NM. Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Front Mol Biosci. 2022;9:836417. DOI: 10.3389/fmolb.2022.836417; PMCID: PMC8824427; PMID: 35145999
3. Gaol DLHL, Rizki KA, Soemitro MP. Incidence Rate and Clinical Characteristics of Triple Negative Breast Cancer Patients in Hasan Sadikin Hospital, for the Last Five Years. J Soc Res. 2023; 2(5):1558-62. DOI: 10.55324/josr.v2i5.845
4. Li S, Bao C, Huang L, Wei JF. Current therapeutic strategies for metastatic triple-negative breast cancer: From pharmacists’ perspective. J Clin Med. 2022;11(20):6021. DOI: 10.3390/jcm11206021; PMCID: PMC9604829; PMID: 36294342
5. Kazmi S, Chatterjee D, Raju D, Hauser R, Kaufman PA. Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine. Breast Cancer Res Treat. 2020;184(2):559-65. DOI: 10.1007/s10549-020-05867-0; PMCID: PMC7599186; PMID: 32808239
6. Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res. 2018;8(5):1483-507. DOI: 10.1007/s13346-018-0551-3; PMCID: PMC6133085; PMID: 29978332
7. Zhang X, Yeung KT. Metastatic Triple-Negative Breast Cancer. Curr Breast Cancer Rep. 2023;15:288-97. DOI: 10.1007/s12609-023-00493-3
8. Krasniqi E, Pizzuti L, Valerio MR, Capomolla E, Botti C, Sanguineti G, et al. Second-line eribulin in triple negative metastatic breast cancer patients. Multicentre retrospective study: the TETRIS trial. Int J Med Sci. 2021;18(10):2245-50. DOI: 10.7150/ijms.54996; PMCID: PMC8040412; PMID: 33859534
9. Asano M, Matsui J, Towle MJ, Wu J, McGonigle S, Boisferon MHDE, et al. Broad-spectrum preclinical antitumor activity of eribulin (Halaven®): combination with anticancer agents of differing mechanisms. Anticancer Res. 2018;38(6):3375-85. DOI: 10.21873/anticanres.12604; PMID: 29848686
10. Kenny L, Beresford M, Brown I, Misra V, Kristeleit H. Eribulin for the treatment of advanced breast cancer: A prospective observational registry study. Eur J Cancer Care. 2022;31(6):e13747. DOI: 10.1111/ecc.13747; PMCID: PMC9787722; PMID: 36336468
11. Zhou Y, Yang J. Narrative review of current status and recommendations in treatment for advanced triple-negative breast cancer. Transl Breast Cancer Res. 2022;3:17. DOI: 10.21037/tbcr-22-12; PMCID: PMC11093051; PMID: 38751541
12. Gui X, Liang X, Li H. Effectiveness, safety, and impact on quality of life of eribulin‐based therapy in heavily pretreated patients with metastatic breast cancer: A real‐world analysis. Cancer Med. 2023;12(6):16793-804. DOI: 10.1002/cam4.6301; PMCID: PMC10501238; PMID: 37403746
13. Garrone O, Miraglio E, Vandone AM, Vanella P, Lingua D, Merlanno MC. Eribulin in advanced breast cancer: safety, efficacy and new perspectives. Futur Oncol. 2017;13(30):2759-69. DOI: 10.2217/fon-2017-0283; PMID: 29219017
14. Tanni KA, Truong CB, Johnson BS, Qian J. Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;163:103375. DOI: 10.1016/j.critrevonc.2021.103375; PMID: 34087344
15. Greenhalgh T, Thorne S, Malterud K. Time to challenge the spurious hierarchy of systematic over narrative reviews? Eur J Clin Invest. 2018;48(6):e12931. DOI: 10.1111/eci.12931; PMCID: PMC6001568; PMID: 29578574
16. Mertz S, Benjamin C, Girvalaki C, Cardone A, Gono P, May SG, et al. Progression-free survival and quality of life in metastatic breast cancer: The patient perspective. Breast. 2022;65:84-90. DOI: 10.1016/j.breast.2022.07.006; PMCID: PMC9307669; PMID: 35870420
17. Ruchalski K, Dewan R, Sai V, McIntosh LJ, Braschi-Amirfarzan M. Imaging response assessment for oncology: An algorithmic approach. Eur J Radiol Open. 2022;9:100426. DOI: 10.1016/j.ejro.2022.100426; PMCID: PMC9184854; PMID: 35693043
18. Subbiah V, Chuang HH, Gambhire D, Kairemo K. Defining clinical response criteria and early response criteria for precision oncology: current state-of-the-art and future perspectives. Diagnostics. 2017;7(1):10. DOI: 10.3390/diagnostics7010010; PMCID: PMC5373019; PMID: 28212290
19. U.S. Department of Health and Human Services. Common terminology criteria for adverse events v5.0. Washington DC: U.S. Department of Health and Human Services; 2017.
20. Le-Rademacher JG, Hillman S, Storrick E, Mahoney MR, Thall PF, Jatoi A, et al. Adverse event burden score a versatile summary measure for cancer clinical trials. Cancers. 2020;12(11):3251. DOI: 10.3390/cancers12113251; PMCID: PMC7694214; PMID: 33158080
21. Masuda N, Ono M, Mukohara T, Yasojima H, Shimoi T, Kobayashi K, et al. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort. Eur J Cancer. 2022;168:108-18. DOI: 10.1016/j.ejca.2022.03.004; PMID: 35500404
22. Pivot X, Marmé F, Koenigsberg R, Guo M, Berrak E, Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol. 2016;27(8):1525-31. DOI: 10.1093/annonc/mdw203; PMCID: PMC4959925; PMID: 27177860
23. Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, et al. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial. Eur J Cancer. 2016;60:117-24. DOI: 10.1016/j.ejca.2016.03.010; PMID: 27107326
24. Mougalian SS, Copher R, Kish JK, McAllister L, Wang Z, Broscious M, et al. Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting. Cancer Med. 2018;7(9):4371-8. DOI: 10.1002/CAM4.1705; PMCID: PMC6144147; PMID: 30066497
25. Dranitsaris G, Gluck S, Faria C, Cox D, Rugo H. Comparative Effectiveness Analysis of Monotherapy with Cytotoxic Agents in Triple-negative Metastatic Breast Cancer in a Community Setting. Clin Ther. 2015;37(1):134-44. 2015. DOI: 10.1016/j.clinthera.2014.10.023; PMID: 25433768
26. Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H, et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10(3):e004291. DOI: 10.1136/jitc-2021-004291; PMCID: PMC8961177; PMID: 35338088
27. Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, et al. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di R. ESMO Open. 2021;6(1):100019. DOI: 10.1016/j.esmoop.2020.100019; PMCID: PMC7808100; PMID: 33399082
28. Lee JS, Yost SE, Blanchard S, Schmolze D, Yin HH, Pillai R, et al. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2019;21(1):119. DOI: 10.1186/s13058-019-1202-4; PMCID: PMC6839083; PMID: 31703728
29. Di Cosimo S, La Verde N, Moretti A, Cazzaniga ME, Generali D, Bianchi GV, et al. Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. PLoS One. 2019;14(8):e0220644. DOI: 10.1371/journal.pone.0220644; PMCID: PMC6685628; PMID: 31390375
30. Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, et al. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. Eur J Cancer. 2019;109:84-91. DOI: 10.1016/j.ejca.2018.11.014; PMID: 30703739
31. Zhou HL, Chen DD. Prognosis of patients with triple-negative breast cancer: a population-based study from SEER database. Clin Breast Cancer. 2023;23(3):e85-94. DOI: 10.1016/j.clbc.2023.01.002; PMID: 36669957
32. Celik A, Berg T, Jensen MB, Nielsen HM, Kümler I, Glavicic V, et al. Real-World Survival and Treatment Regimens Across First-to Third-Line Treatment for Advanced Triple-Negative Breast Cancer. Breast Cancer Basic Clin Res. 2023;17:11782234231203292. DOI: 10.1177/11782234231203292; PMCID: PMC10552450; PMID: 37810797
33. Skinner KE, Haiderali A, Huang M, Schwartzberg LS. Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer. Futur Oncol. 2021;17(8):931-41. DOI: 10.2217/fon-2020-1021; PMID: 33207944
34. Kesireddy M, Elsayed L, Shostrom VK, Agarwal P, Asif S, Yellala A, et al. Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis. Cancers, 2024;16(10):1791. DOI: 10.3390/cancers16101791; PMCID: PMC11120599; PMID: 38791870
35. O’Shaughnessy J, Cortes J, Twelves C, Goldstein LJ, Alexis K, Xie R, et al. Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. Sci Rep. 2020;10(1):11203. DOI: 10.1038/s41598-020-66980-0; PMCID: PMC7343788; PMID: 32641747
36. Oey O, Wijaya W, Redfern A. Eribulin in breast cancer: Current insights and therapeutic perspectives. World J Exp Med. 2024;14(2):92558. DOI: 10.5493/wjem.v14.i2.92558; PMCID: PMC11212747; PMID: 38948420
37. Giulietti M, Piva F, Cecati M, Maggio S, Guescini M, Saladino T, et al. Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells. Cells. 2024;13(6):479. DOI: 10.3390/cells13060479; PMCID: PMC10969587; PMID: 38534323
38. O’Shaughnessy J, Kaklamani V, Kalinsky K. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. Futur Oncol. 2019;15(14):1641-53. DOI: 10.2217/fon-2018-0936; PMID: 30892083
39. Takahashi-Ruiz L, Fermaintt CS, Wilkinson NJ, Chen PYW, Mooberry SL, Risinger AL. The microtubule destabilizer eribulin synergizes with STING agonists to promote antitumor efficacy in triple-negative breast cancer models. Cancers. 2022;14(23):5962. DOI: 10.3390/cancers14235962; PMCID: PMC9740651; PMID: 36497445
40. Yuan P, Xu B. Clinical utility of eribulin mesylate in the treatment of breast cancer: A Chinese perspective. Breast Cancer Targets Ther. 2021;13:135-50. DOI: 10.2147/BCTT.S231298; PMCID: PMC7917473; PMID: 33658845
41. Zhang R, Chen Y, Liu X, Gui X, Zhu A, Jiang H, et al. Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting. Front Oncol. 2023;13:1076469. DOI: 10.3389/fonc.2023.1076469; PMCID: PMC10314217; PMID: 37397355
42. Jiang M, Shao B, Wan D, Liu J, He M, Chai Y, et al. Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study. Ther Adv Med Oncol. 2023;15:17588359231204856. DOI: 10.1177/17588359231204856; PMCID: PMC10571693; PMID: 37841751
43. Huang W, Wang C, Shen Y, Chen Q, Huang Z, Liu J, et al. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer. BMC Cancer. 2024;24(1):39. DOI: 10.1186/s12885-023-11790-6; PMCID: PMC10768098; PMID: 38182995
44. Wang K, Yang J, Wang B, Liu Q, Wang X, Yin Y, et al. Expert consensus on the clinical application of immunotherapy in breast cancer: 2024. Transl Breast Cancer Res. 2024;5:9. DOI: 10.21037/tbcr-24-15; PMCID: PMC11094404; PMID: 38751677
45. Ou Y, Wang M, Xu Q, Sun B, Jia Y. Small molecule agents for triple negative breast cancer: Current status and future prospects. Transl Oncol. 2024;41:101893. DOI: 10.1016/j.tranon.2024.101893; PMCID: PMC10840364; PMID: 38290250
46. DiPiro JT, Yee GC, Haines ST, Niolin TD, Ellingrod VL, Posey M. DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, 12th Edition. New York: McGraw Hill; 2023.
47. Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121. DOI: 10.1186/s13045-022-01341-0; PMCID: PMC9422136; PMID: 36038913
48. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727-42. PMCID: PMC7136921; PMID: 32266087
49. Marra A, Trapani D, Viale G, Cristiciello C, Curigliano G. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer. 2020;6:54. DOI: 10.1038/s41523-020-00197-2; PMCID: PMC7568552; PMID: 33088912
50. Chen Z, Lu X, Koral K. The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2020;14(11):1017-24. DOI: 10.1080/17474124.2020.1807939; PMID: 32762583
51. Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475-95. DOI: 10.1016/j.annonc.2021.09.019; PMID: 34678411
52. Telli ML, Gradishar WJ, Ward JH. NCCN Guidelines Updates: Breast Cancer. J Natl Compr Canc Netw. 2019;17(5.5):552-5. DOI: 10.6004/jnccn.2019.5006; PMID: 31117035
53. Gradishar W, Salerno KE. NCCN Guidelines Update: Breast Cancer. J Natl Compr Canc Netw. 2016;14(5 Suppl):641-4. DOI: 10.6004/jnccn.2016.0181; PMID: 27226503
54. Heeke AL, Tan AR. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. Cancer Metastasis Rev. 2021;40(2):537-47. DOI: 10.1007/s10555-021-09972-4; PMCID: PMC8184866; PMID: 34101053
55. López-Álvarez M, González-Aguilera C, Moura DS, Sánchez-Bustos P, Mondaza-Hernández JL, Martín-Ruiz M, et al. Efficacy of eribulin plus gemcitabine combination in L-sarcomas. Int J Mol Sci. 2022;24(1):680. DOI: 10.3390/ijms24010680; PMCID: PMC9820645; PMID: 36614121
56. Lheureux S, Oza AM, Laurie SA, Halford R, Jonker D, Chen E, et al. A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium. Br J Cancer. 2015;113(11):1534-40. DOI: 10.1038/bjc.2015.343; PMCID: PMC4705880; PMID: 26554651
57. Manousakis E, Miralles CM, Esquerda MG, Wright RGH. CDKN1A/p21 in Breast Cancer: Part of the Problem, or Part of the Solution? Int J Mol Sci. 2023;24(24):17488. DOI: 10.3390/ijms242417488; PMCID: PMC10743848; PMID: 38139316
58. El Guerrab A, Bamdad M, Bignon YJ, Penault-Llorca F, Aubel C. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells. Sci Rep. 2020;10:6367. DOI: 10.1038/s41598-020-63310-2; PMCID: PMC7156377; PMID: 32286420
59. Zhang H, Jiang R, Zhu J, Sun KN, Huang Y, Zhou HH, et al. PI3K/AKT/mTOR signaling pathway: An important driver and therapeutic target in triple-negative breast cancer. Breast Cancer. 2024;31(4):539-51. DOI: 10.1007/s12282-024-01567-5; PMCID: PMC11194209; PMID: 38630392
60. Roviello G, Milani M, Gobbi A, Cappelletti MR, Zanotti L, Senti C, et al. A phase Ib open-label study to assess the safety and tolerability of everolimus in combination with eribulin in triple-negative breast cancers. Clin Breast Cancer. 2016;16(3):e57-9. DOI: 10.1016/j.clbc.2016.02.012; PMID: 26943987
61. Mazumdar A, Tahaney WM, Hill JL, Zhang Y, Ramachandran S, Kawedia J, et al. Targeting the mTOR pathway for the prevention of ER-negative breast cancer. Cancer Prev Res. 2022;15(12):791-802. DOI: 10.1158/1940-6207.CAPR-22-0106; PMCID: PMC9762336; PMID: 35981902
62. He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):425. DOI: 10.1038/s41392-021-00828-5; PMCID: PMC8677728; PMID: 34916492
63. Yang R, Li Y, Wang H, Qin T, Yin X, Ma X. Therapeutic progress and challenges for triple negative breast cancer: Targeted therapy and immunotherapy. Mol Biomed. 2022;3(1):8. DOI: 10.1186/s43556-022-00071-6; PMCID: PMC8894518; PMID: 35243562
64. Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol. 2019;30(7):1051-60. DOI: 10.1093/annonc/mdz133; PMID: 31050709
65. Wen W, Marcinkowski E, Luyimbazi D, Luu T, Xing Q, Yan J, et al. Eribulin synergistically increases anti-tumor activity of an mTOR inhibitor by inhibiting pAKT/pS6K/pS6 in triple negative breast cancer. Cells. 2019;8(9):1010. DOI: 10.3390/cells8091010; PMCID: PMC6770784; PMID: 31480338
66. Seshadri P, Deb B, Kumar P. Multifarious targets beyond microtubules—role of eribulin in cancer therapy. Front Biosci. 2021;13(2):157-72. DOI: 10.52586/S559; PMID: 34879468
67. Lin YY, Gao HF, Yang X, Zhu T, Zheng XX, Ji F, et al. Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis. Breast. 2022;66. DOI: 10.1016/j.breast.2022.08.006; PMCID: PMC9587342; PMID: 36265208
68. Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer. 2016;10:25-36. DOI: 10.4137/BCBCR.S32783; PMCID: PMC4807882; PMID: 27042088
69. Sharif-Askari B, Panasci L, Aloyz R. PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin. Front Biosci. 2023;28(3):52. DOI: 10.31083/j.fbl2803052; PMID: 37005765
70. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017; 377(6):523-33. DOI: 10.1056/NEJMoa1706450; PMID: 28578601
71. Zerdan MB, Ghorayeb T, Saliba F, Allam S, Zerdan MB, Yaghi M, et al. Triple negative breast cancer: updates on classification and treatment in 2021. Cancers. 2022;14(5):1253. DOI: 10.3390/cancers14051253; PMCID: PMC8909187; PMID: 35267561
72. Swami U, Shah U, Goel S. Eribulin in cancer treatment. Mar Drugs. 2015;13(8):5016-58. DOI: 10.3390/md13085016; PMCID: PMC4557013; PMID: 26262627
73. Ro J, Cheng FTF, Sriuranpong V, Villalon A, Smruti BK, Tsang J, et al. Patient management with eribulin in metastatic breast cancer: a clinical practice guide. J Breast Cancer. 2016;19(1):8-17. DOI: 10.4048/jbc.2016.19.1.8; PMCID: PMC4822111; PMID: 27066091
74. Chen C, Wang J, Zhao Q. Hematologic adverse events (HAEs) of Eribulin used in treating metastatic breast cancer (MBC): a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2018;11(6):5409-17.
75. Aytan J, Bukhari MAS. Review Use of biologics in SLE: a review of the evidence from a clinical perspective. Rheumatology. 2016;55(5):775-9. DOI: 10.1093/rheumatology/kev346; PMID: 26424838
76. Perez-Garcia JM, Cortes J. The safety of eribulin for the treatment of metastatic breast cancer. Expert Opin Drug Saf. 2019;18(5):347-55. DOI: 10.1080/14740338.2019.1608946; PMID: 31107111
77. Strom BL, Kimmel SE, Hennessy S. Textbook of Pharmacoepidemiology. 3rd Edition. Chichester: John Wiley & Sons; 2022.
Authors
1.
Meriyani H, Sanjaya DA, Juanita RA, Siada NB, Chusna N. Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review. Borneo J Pharm [Internet]. 2025Feb.28 [cited 2025Mar.17];8(1):33-48. Available from: https://journal.umpr.ac.id/index.php/bjop/article/view/7913
Copyright (c) 2025 Herleeyana Meriyani, Dwi Arymbhi Sanjaya, Rr. Asih Juanita, Nyoman Budiartha Siada, Nurul Chusna
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors continue to retain the copyright to the article if the article is published in the Borneo Journal of Pharmacy. They will also retain the publishing rights to the article without any restrictions.
Authors who publish in this journal agree to the following terms:
- Any article on the copyright is retained by the author(s).
- The author grants the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share work with an acknowledgment of the work authors and initial publications in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of published articles (e.g., post-institutional repository) or publish them in a book, with acknowledgment of their initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their websites) prior to and during the submission process. This can lead to productive exchanges and earlier and greater citations of published work.
- The article and any associated published material are distributed under the Creative Commons Attribution-ShareAlike 4.0 International License.
Article Details
